about
sameAs
Targeting neuropilin-1 in human leukemia and lymphomaRole of the tumor microenvironment in mature B-cell lymphoid malignanciesExtramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B-LBL): a diagnostic challengeProgress in acute myeloid leukemiaCharacteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemiaDasatinib in imatinib-resistant Philadelphia chromosome-positive leukemiasNilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALLPhase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemiaFeasibility of therapy with hypomethylating agents in patients with renal insufficiencyJAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasmsImatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trMolecular differences between small and large cells in patients with chronic lymphocytic leukemia.Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia.Combinatorial targeting of the macropinocytotic pathway in leukemia and lymphoma cells.Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia.The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome.2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.Phase I trial of nelarabine in indolent leukemias.Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemChemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemiaBleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia.Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasmsResults of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialFCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia.
P50
Q24620098-57E6ABF7-41C9-4810-A3CB-E5F5DF1415FFQ26748775-C31E6173-1E00-4CC5-A587-8B288285BC44Q27005996-9A2C31F9-E26A-4E00-8B35-9612867922B0Q27024006-50B4DFB3-CD85-4BBB-9D2F-193E9E970953Q27851450-55B41A68-BB64-465D-A722-2B56529FCB64Q28189439-D7E1D927-0808-4BE5-B11C-D36DE5032E47Q28246193-FC4856D5-3849-4802-861B-4F891CBC835DQ28246204-AE05B7B3-8D05-460E-BB09-5746BF589265Q28261949-54B578C3-40EE-4F52-85EF-FA197928C79EQ28283836-4D628506-1115-458D-A5ED-F4F64046BC43Q28749690-6D3F8AC8-F1C2-49F0-AF85-96587B94E6E1Q30885947-12520B80-C0DC-4CF7-B540-F6B09144F813Q31033077-54EC87D3-D0B0-48D4-938C-0CA93815FE90Q31155471-0D41BDC9-B8C1-420A-B1D2-C2C76C974E40Q33235545-F0D04A3D-752C-44DC-A224-B762C020D83EQ33320806-CFCA7C38-4A0B-46E2-A8EA-B855A6D750A3Q33341768-29003FDE-8A55-4842-BE0B-5DD64B052261Q33343726-60660CF3-CFAD-4775-8DCC-214ED202F160Q33345782-CB9E086E-1D5B-4AC5-9FE6-2C31E6256D5EQ33358304-4ADAFFB9-7161-46FA-8253-6CFAED611F6DQ33360750-9B6AC4F1-91B6-430B-86C4-1E8754323A64Q33366921-E182BA86-4427-41AB-A5F5-F257B0D04142Q33371900-202B4DD3-136F-4407-9DE5-A2F42029040DQ33376638-902B470E-F3CC-472E-B82C-4D21E8ADECADQ33378808-282A19CD-1CEE-49E0-B3A8-69D8F2F5F9CEQ33380307-5095EB70-3DBA-41CC-A030-AB0A7318BF08Q33382608-1E15D70D-7752-427F-A956-15CA66179C19Q33383664-8A6841C5-0378-4FEF-A5A3-383136E81D6FQ33384955-9069EB63-25FD-4679-934C-E2821A6ED8DFQ33385566-E2D5EFFA-747F-4774-9FCE-CCD8B926BA2DQ33386506-B3157E3A-D469-48B8-9FE3-04951DF15539Q33387517-DC816B80-C02C-495A-851A-CCFFF745AD82Q33387519-A65C828A-C7A5-47F0-9FB3-9D9B26316EDDQ33390293-C98D21C0-8044-434B-BACE-C6B18C4D572CQ33392185-21FE37E1-8B09-42E2-945A-FCDD93126A9EQ33395333-4A5C48F2-2333-4D9F-AFF4-48486C477E86Q33396222-0F24BDFA-4B6B-4261-99EF-38341BC8940DQ33412064-B82639A5-899E-4287-BA73-2A17BC8A8C7EQ33416596-8504BABA-1938-40AA-9A96-5AA769071403Q33421376-B8157DCE-A5C5-429E-BDB5-F67DC344EE75
P50
description
Narozena 25. 10. 1954, M.D., americká lékařka, zabývá se onkologií. Publikuje v oboru.
@cs
name
Susan O'Brien
@ast
Susan O'Brien
@cs
Susan O'Brien
@de
Susan O'Brien
@en
Susan O'Brien
@nl
Susan O'Brien
@sk
type
label
Susan O'Brien
@ast
Susan O'Brien
@cs
Susan O'Brien
@de
Susan O'Brien
@en
Susan O'Brien
@nl
Susan O'Brien
@sk
prefLabel
Susan O'Brien
@ast
Susan O'Brien
@cs
Susan O'Brien
@de
Susan O'Brien
@en
Susan O'Brien
@nl
Susan O'Brien
@sk
P214
P5361
P106
P21
P214
P31
P5361
OBrienSusan1954-
P569
1954-10-25T00:00:00Z
P691
P734
P735
P7859
lccn-n2008183079